Anavex Submits Marketing Authorization Application for Blarcamesine in Alzheimer Disease in the EU
According to a new announcement, Anavex Life Sciences has submitted its marketing authorization application (MAA) for blarcamesine, a small molecule activator of the sigma-1 receptor (SIGMAR1), as a potential treatment for patients with Alzheimer disease ( …